• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Liminal BioSciences downgraded by H.C. Wainwright

    6/24/21 7:18:08 AM ET
    $LMNL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LMNL alert in real time by email
    H.C. Wainwright downgraded Liminal BioSciences from Buy to Neutral
    Get the next $LMNL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LMNL

    DatePrice TargetRatingAnalyst
    6/24/2021Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $LMNL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Liminal BioSciences downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Liminal BioSciences from Buy to Neutral

      6/24/21 7:18:08 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Liminal Biosciences downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Liminal Biosciences from Overweight to Neutral and set a new price target of $4.50 from $22.00 previously

      6/2/21 6:25:42 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright initiated coverage on Liminal BioSciences with a new price target

      HC Wainwright initiated coverage of Liminal BioSciences with a rating of Buy and set a new price target of $11.00

      2/25/21 10:46:46 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LMNL
    SEC Filings

    See more
    • SEC Form 15-12G filed by Liminal BioSciences Inc.

      15-12G - Liminal BioSciences Inc. (0001351172) (Filer)

      10/6/23 8:30:57 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Liminal BioSciences Inc.

      EFFECT - Liminal BioSciences Inc. (0001351172) (Filer)

      9/27/23 12:15:18 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Liminal BioSciences Inc.

      EFFECT - Liminal BioSciences Inc. (0001351172) (Filer)

      9/27/23 12:15:20 AM ET
      $LMNL
      Biotechnology: Pharmaceutical Preparations
      Health Care